Sophie Kornowski
CIK: 0001894117
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
MAZE
Maze Therapeutics, Inc.
Director
Discretionary Trading P&L
Holdings
About Kornowski Sophie
Kornowski Sophie (SEC CIK 0001894117) files insider reports with the SEC as Director of Maze Therapeutics, Inc. (MAZE).
Signal8 holds 2 ownership filings by Kornowski Sophie (1 Form 3, 1 Form 4), filed on Aug 17, 2026. Those filings report 1 transaction, the latest on Aug 13, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Kornowski Sophie's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Kornowski Sophie
- Aug 13, 2026: Grant or award of MAZE derivative securities (Form 4, code A).
Other insiders filing for Maze Therapeutics, Inc. (MAZE)
- Dandekar Atul, CSBO
- Coloma Jason V, Chief Executive Officer
- Bernstein Harold, President, R&D & CMO
- Courtney Phillips, GC and Corp. Secretary
- Johnson Paula A, Director
- SPIEGELMAN DANIEL K, Director